Willingness to pay
40% would pay €2,500 out of pocket
for digital ADHD assessments (n=640 survey)
› n=640› Sweden› 2025
LUMENA NEUROPSYKIATRI
Solving the European ADHD crisis
With compliant D2C specialist care for millions. No waitlists, no geographical barriers.
Lars Lööf, CEO and founder
+4672 321 22 99
lars@lumena.se
THE PROBLEM
A broken system
- 7% of the population suffer from ADHD
- ~60% are untreated
- 7-year wait times in public care
- Private options lack accessibility or regulatory compliance
CDC / MMWR, 2024
NCBI / PMC, 2014
Socialstyrelsen, 2024
THE COST
The human and economic toll
€400B
annual cost to European society
5×
higher suicide attempt risk
PubMed, 2019
PubMed, 2021
THE INSIGHT
Queues and distance stop people. Not money.
SVT Nyheter, 2026
THE SOLUTION
We make Compliant + Remote possible
Digital specialists
inhouse
+
Physical generalist
partners
- Other digital players skip physical elements, failing regulatory standards.
- We bridge the gap. We connect decentralized specialists with a strategic network of third party physical clinics.
- We are the first to successfully execute this compliant, hybrid approach at scale.
THE TEAM
Clinical excellence combined with execution
Lars L
CEO
Financials, Growth & Strategy
- Former scale-up operator & marketing agency exec
- 12+ years experience
Josefine B
Unit Manager
People & Operations
- Former Psychiatry Unit Manager
- 12+ years experience
Paul B
Chief Medical
Clinical Compliance & Protocols
- Serial psychiatry entrepreneur
- 25+ years experience
Peter K
Sr. Psychiatrist
Clinical Recruitment & Education
- Former Head of Psychiatry, Dalarna
- 25+ years experience
EARLY VALIDATION
The foundation has been built
Over the last year we've:
- Built a fully functional tech infrastructure for providing care remotely
- Signed 150+ binding agreements with testing units
- Signed 15+ binding agreements with local doctor's clinics
- Implemented automation and AI to improve efficiency
150+ locations across Sweden
EARLY VALIDATION
And it has been tested
€765 CAC
Customer Acquisition Cost over 16k spend
65%
Conversion rate, assessment to medication
23
Assessments completed
€30k
Revenue with near-zero overhead
THE PRODUCT
We didn't build the interface
- Tech-enabled: Utilization of off-the-shelf software (EMR, AI). No CAPX. We're not building expensive software.
- Single workflow (neuro care): We're strong vs. generalists care companies, punching above our weight.
- Scaleable: Low OPEX. Specialists work 100% remotely.
PRODUCT
We built the engine
We partner with local clinics and testing units to reach more people. Each partnership is binding with pre-declared standard operating procedures.
BUSINESS MODEL
100% private pay, up front.
BUSINESS MODEL
The assessment is just the beginning
- Recurring Revenue: Zero cost conversion to long-term treatment (MRR) with low churn.
- Our compounding MRR cohort provides financial stability.
COMPETITIVE MOAT
The Innovators Dilemma
- Trad competitors: have sunk cost in admin/facilities.
- Digital competitors: have sunk cost in brand promise of speed and ease-of-use.
- Second movers: Our traditional healthcare partners demand clinical orchestration, which pure-tech founders lack.
COMPETITION
The "Compliant + Remote Monopoly"
Public care Region Stockholm · NHS · WeMind | Digital private Psykiatrispecialisterna · GAM Medical · ADHD 360 | Traditional private Psykiatripartner · Modigo · Oberberg Kliniken | Lumena | |
|---|---|---|---|---|
| Waitlist | 7 years | 7 days | 14 days | 7 days |
| Compliance | Compliant | Not compliant | Compliant | Compliant |
| Localization | In person care | Anywhere | In person care | Anywhere |
| Continuity | Fragmented care | Fragmented care | End-to-end | End-to-end |
THE MARKET
A global issue, with clear EU legislative framework.
- TAM — Total EU Market: 24.5 million adults / ≈ €79 billion
- SAM — Northern Europe Private Market: 1.9 million adults / ≈ €6.1 billion
- SOM — Nordic Private Market (18-Month Focus): 280,000 adults / ≈ €900M
€455k GTM budget / €765 CAC = ~500–600 out-of-pocket assessments secured in the next 12–18 months
SCALING
One physical space per country. Everything else is remote.
Internationalizing healthcare always requires country-by-country staff, electronic medical records and legal.
Our upside is that we can do so with a single physical space in each country. Hiring and production is decentralized.
FINANCIALS
Path to Scale
- Current State: €18k MRR run-rate, validated clinical workflows. Circa 8 assessments per month.
- Target (12 months): Break-even at 25 assessments/month.
Key value inflection points for the next 18 months.
1
Value Inflection 1: Shifting production to inhouse. From 15 to 50 percent Gross Margin.
2
Value Inflection 2: Reaching breakeven at 25 assessments.
3
Value Inflection 3: Platform for expansion secured in starting market.
THE ASK
Fueling the European rollout.
€650,000
Raising
16%
Target dilution
4.2×
LTV:CAC
70%
GTM & Acquisition
Fueling the validated acquisition engine to dominate the Nordic market window.
20%
Ops & CVR Optimization
Streamlining the patient journey to drive conversion rates.
10%
Key Hires
Securing early strategic roles.
Targeting larger round for DACH/UK expansion.
Lars Lööf, CEO and founder
+4672 321 22 99
lars@lumena.se